Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat

Read the full 286 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE